Meeting
2024 ASCO Genitourinary Cancers Symposium
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
Authors
Karim Fizazi
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France
Karim Fizazi , Neal D. Shore , Peter C.C. Fong , Arun Azad , Nobuaki Matsubara , Fred Saad , Ugo De Giorgi , Jae Young Joung , Robert J. Jones , Stefanie Zschaebitz , Jan Oldenburg , Curtis Dunshee , Joan Carles , Andre P. Fay , Paul Cislo , Melissa Kirker , Cynthia G. Healy , Alexander Niyazov , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT03395197
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 109)
DOI
10.1200/JCO.2024.42.4_suppl.109
Abstract #
109
Poster Bd #
E2
Abstract Disclosures
Similar Posters
First Author: Arun Azad
Poster
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
First Author: Elena Castro